Vector Design for Improved DNA Vaccine Efficacy, Safety and Production
Open Access
- 25 June 2013
- Vol. 1 (3) , 225-249
- https://doi.org/10.3390/vaccines1030225
Abstract
DNA vaccination is a disruptive technology that offers the promise of a new rapidly deployed vaccination platform to treat human and animal disease with gene-based materials. Innovations such as electroporation, needle free jet delivery and lipid-based carriers increase transgene expression and immunogenicity through more effective gene delivery. This review summarizes complementary vector design innovations that, when combined with leading delivery platforms, further enhance DNA vaccine performance. These next generation vectors also address potential safety issues such as antibiotic selection, and increase plasmid manufacturing quality and yield in exemplary fermentation production processes. Application of optimized constructs in combination with improved delivery platforms tangibly improves the prospect of successful application of DNA vaccination as prophylactic vaccines for diverse human infectious disease targets or as therapeutic vaccines for cancer and allergy.Keywords
This publication has 121 references indexed in Scilit:
- Immunogenicity and clinical protection against equine influenza by DNA vaccination of poniesVaccine, 2012
- New Generation of Plasmid Backbones Devoid of Antibiotic Resistance Marker for Gene Therapy TrialsMolecular Therapy, 2011
- The Actin Cytoskeleton Has an Active Role in the Electrotransfer of Plasmid DNA in Mammalian CellsMolecular Therapy, 2011
- Electroporation delivery of DNA vaccines: prospects for successCurrent Opinion in Immunology, 2011
- Critical design criteria for minimal antibiotic‐free plasmid vectors necessary to combine robust RNA Pol II and Pol III‐mediated eukaryotic expression with high bacterial production yieldsThe Journal of Gene Medicine, 2010
- Identification and removal of colanic acid from plasmid DNA preparations: implications for gene therapyGene Therapy, 2010
- Improved antibiotic-free DNA vaccine vectors utilizing a novel RNA based plasmid selection systemVaccine, 2009
- Generic plasmid DNA production platform incorporating low metabolic burden seed‐stock and fed‐batch fermentation processesBiotechnology & Bioengineering, 2009
- Plasmid DNA vaccine vector design: Impact on efficacy, safety and upstream productionBiotechnology Advances, 2009
- Heterologous HA DNA vaccine prime—inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza virusesVaccine, 2008